The outbreak stemmed from contaminated medication from the New England Compounding Center in Framingham, Mass. As of March 4, CDC had received 720 reports of fungal meningitis, including 48 deaths, from 20 states. Based on input from expert consultants and physicians who have treated affected patients, CDC revised its “Interim Treatment and Diagnostic Guidance for Central Nervous System and Parameningeal Infections Associated with Injection of Contaminated Steroid Products.” The revisions include new information on several topics, including the following:
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
• Non first-line medications
• Surgical management of parameningeal disease
• Duration of anti-fungal treatment
• Monitoring after cessation of anti-fungal treatment
More Articles on Fungal Meningitis Outbreak:
CDC Identifies Contamination in More Medical Products From New England Compounding Center
Compounding Pharmacy Oversight Under Fire by Senate Committee
“Bureaucratic Inertia” to Blame in NECC’s Continued Operation, Senate Committee Says
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
